TG Therapeutics Statistics Share Statistics TG Therapeutics has 158.75M
shares outstanding. The number of shares has increased by 2.54%
in one year.
Shares Outstanding 158.75M Shares Change (YoY) 2.54% Shares Change (QoQ) 1.07% Owned by Institutions (%) 66.93% Shares Floating 142.98M Failed to Deliver (FTD) Shares 2,940 FTD / Avg. Volume 0.15%
Short Selling Information The latest short interest is 24.17M, so 15.22% of the outstanding
shares have been sold short.
Short Interest 24.17M Short % of Shares Out 15.22% Short % of Float 19.91% Short Ratio (days to cover) 16.85
Valuation Ratios The PE ratio is 187.06 and the forward
PE ratio is 15.51.
TG Therapeutics's PEG ratio is
2.36.
PE Ratio 187.06 Forward PE 15.51 PS Ratio 13.29 Forward PS 5 PB Ratio 19.67 P/FCF Ratio -107.84 PEG Ratio 2.36
Financial Ratio History Enterprise Valuation TG Therapeutics has an Enterprise Value (EV) of 4.45B.
EV / Sales 13.52 EV / EBITDA 89.15 EV / EBIT -109.79 EV / FCF -109.67
Financial Position The company has a current ratio of 6.25,
with a Debt / Equity ratio of 1.14.
Current Ratio 6.25 Quick Ratio 5.03 Debt / Equity 1.14 Debt / EBITDA 5.1 Debt / FCF -6.27 Interest Coverage 1.75
Financial Efficiency Return on Equity is 10.52% and Return on Invested Capital is 7.84%.
Return on Equity 10.52% Return on Assets 4.05% Return on Invested Capital 7.84% Revenue Per Employee $934.67K Profits Per Employee $66.43K Employee Count 352 Asset Turnover 0.57 Inventory Turnover 0.35
Taxes Income Tax 2.21M Effective Tax Rate 8.64%
Stock Price Statistics The stock price has increased by 27.85% in the
last 52 weeks. The beta is 1.95, so TG Therapeutics's
price volatility has been higher than the market average.
Beta 1.95 52-Week Price Change 27.85% 50-Day Moving Average 36.06 200-Day Moving Average 34.17 Relative Strength Index (RSI) 21.97 Average Volume (20 Days) 1,993,374
Income Statement In the last 12 months, TG Therapeutics had revenue of 329M
and earned 23.38M
in profits. Earnings per share was 0.16.
Revenue 329M Gross Profit 290.52M Operating Income 41.93M Net Income 23.38M EBITDA 49.9M EBIT 49.62M Earnings Per Share (EPS) 0.16
Full Income Statement Balance Sheet The company has 179.89M in cash and 254.38M in
debt, giving a net cash position of -74.49M.
Cash & Cash Equivalents 179.89M Total Debt 254.38M Net Cash -74.49M Retained Earnings -1.53B Total Assets 656.69M Working Capital 484.3M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -40.52M
and capital expenditures -45K, giving a free cash flow of -40.56M.
Operating Cash Flow -40.52M Capital Expenditures -45K Free Cash Flow -40.56M FCF Per Share -0.28
Full Cash Flow Statement Margins Gross margin is 88.3%, with operating and profit margins of 12.74% and 7.11%.
Gross Margin 88.3% Operating Margin 12.74% Pretax Margin 7.78% Profit Margin 7.11% EBITDA Margin 15.17% EBIT Margin 12.74% FCF Margin -12.33%
Dividends & Yields TGTX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield 0.53% FCF Yield -0.93%
Dividend Details Analyst Forecast The average price target for TGTX is $46.5,
which is 76.1% higher than the current price. The consensus rating is "Buy".
Price Target $46.5 Price Target Difference 76.1% Analyst Consensus Buy Analyst Count 4
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number 2.35 Graham Upside -91.1%
Stock Splits The last stock split was on Apr 30, 2012. It was a
backward
split with a ratio of 4:225.
Last Split Date Apr 30, 2012 Split Type backward Split Ratio 4:225
Scores Altman Z-Score 4.88 Piotroski F-Score 2
